Market closed
Regeneron/$REGN
Regeneron shares are trading higher after the company announced a $3 billion agreement with Fujifilm Diosynth to boost U.S. manufacturing capacity.
2 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15,106
Website
Regeneron Metrics
BasicAdvanced
$60B
14.65
$38.34
0.27
$0.88
0.63%
Price and volume
Market cap
$60B
Beta
0.27
52-week high
$1,206.81
52-week low
$525.99
Average daily volume
1.1M
Dividend rate
$0.88
Financial strength
Current ratio
5.567
Quick ratio
4.935
Long term debt to equity
9.908
Total debt to equity
10.012
Interest coverage (TTM)
76.58%
Management effectiveness
Return on assets (TTM)
7.31%
Return on equity (TTM)
15.95%
Valuation
Price to earnings (TTM)
14.645
Price to revenue (TTM)
4.266
Price to book
2.06
Price to tangible book (TTM)
2.14
Price to free cash flow (TTM)
17.12
Dividend yield (TTM)
0.16%
Forward dividend yield
0.63%
Growth
Revenue change (TTM)
8.27%
Earnings per share change (TTM)
10.27%
3-year revenue growth (CAGR)
-4.04%
3-year earnings per share growth (CAGR)
-18.94%
What the Analysts think about Regeneron
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Regeneron Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Regeneron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Regeneron News
AllArticlesVideos
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Barrons·6 hours ago
Regeneron signs over $3 billion deal with contract drugmaker to boost US manufacturing
Reuters·11 hours ago
FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion
Business Wire·11 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $60B as of April 22, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 14.65 as of April 22, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of April 22, 2025, the dividend rate is $0.88 and the yield is 0.63%. Regeneron has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment date is unconfirmed.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.